These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 16113786)

  • 1. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
    Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
    Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma.
    Koestenberger M; Cvirn G; Gallistl S; Kutschera J; Muntean W
    Acta Paediatr; 2005 Jul; 94(7):884-9. PubMed ID: 16188810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time.
    Koestenberger M; Cvirn G; Gallistl S; Muntean W
    Blood Coagul Fibrinolysis; 2004 Oct; 15(8):693-7. PubMed ID: 15613925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drotrecogin alfa (activated, Xigris) in combination with heparin or melagatran: an in vitro investigation.
    Koestenberger M; Cvirn G; Gallistl S; Baier K; Leschnik B; Muntean W
    J Thromb Thrombolysis; 2004 Aug; 18(1):5-10. PubMed ID: 15744547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
    Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
    Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anticoagulant action of recombinant human activated protein C (rhAPC, Drotrecogin alpha activated): comparison between cord and adult plasma.
    Cvirn G; Gallistl S; Koestenberger M; Baier K; Fritsch P; Greilberger J; Jürgens G; Muntean W
    Thromb Haemost; 2004 May; 91(5):912-8. PubMed ID: 15116251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
    Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
    Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin.
    Furugohri T; Morishima Y
    Thromb Res; 2015 Sep; 136(3):658-62. PubMed ID: 26188924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
    Elg M; Carlsson S; Gustafsson D
    Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
    Wolzt M; Levi M; Sarich TC; Boström SL; Eriksson UG; Eriksson-Lepkowska M; Svensson M; Weitz JI; Elg M; Wåhlander K
    Thromb Haemost; 2004 Jun; 91(6):1090-6. PubMed ID: 15175794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
    Mattsson C; Menschiek-Lundin A; Wåhlander K; Lindahl TL
    Thromb Haemost; 2001 Aug; 86(2):611-5. PubMed ID: 11522011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of melagatran on activated partial thromboplastin time and on ecarin clotting time in cord versus adult plasma.
    Koestenberger M; Gallistl S; Bettina L; Cimenti C; Kutschera J; Cvirn G
    Blood Coagul Fibrinolysis; 2006 Nov; 17(8):677-80. PubMed ID: 17102656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.
    Johansson S; Wåhlander K; Larson G; Ohlsson L; Larsson M; Eriksson UG
    Blood Coagul Fibrinolysis; 2003 Oct; 14(7):677-84. PubMed ID: 14517494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant action of melagatran: a comparison between neonates and adults using calibrated automated thrombography (CAT).
    Cvirn G; Cimenti C; Kutschera J; Ferstl U; Wagner T; Muntean W; Jurgens G; Gallistl S; Koestenberger M
    Eur J Pediatr; 2007 May; 166(5):427-31. PubMed ID: 17047995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
    Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
    Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
    Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
    Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats.
    Furugohri T; Fukuda T; Tsuji N; Kita A; Morishima Y; Shibano T
    Eur J Pharmacol; 2012 Jul; 686(1-3):74-80. PubMed ID: 22546231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.